Close

iNova Pharmaceuticals launches iPITCH 2024 – a global crowdsourcing initiative

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...
- Advertisement -

iNova Pharmaceuticals, in partnership with CoVentured, is thrilled to launch ‘iPitch 2024’, a global crowdsourcing initiative which aims to discover the latest, science-backed innovations in the field of ‘wound care’.

iPitch offers product and packaging developers, innovators, research and development labs, licensors and certified manufacturers the opportunity to connect with iNova and showcase innovative consumer health products that have the potential for commercialisation.

It provides a wonderful opportunity for anyone with new, unique or next-generation solutions, but who may not have the resources or expertise to bring their innovations to market, or are looking for an experienced, global commercialisation partner with a strong track-record of success.

Filomena Maiese, iNova Executive Director – Portfolio Strategy & Innovation, said “This is an exciting time of growth for iNova as we launch into new consumer health categories and expand our geographic reach following the acquisition of the iconic BETADINE portfolio from Mundipharma International earlier this year.”

After creating a lot of buzz in 2020, and by leveraging the power of global connectivity, the previous iPitch initiative executed by iNova received hundreds of diverse product and formulation ideas from around the world. As a result, iNova launched new products, which otherwise would not have had a chance to make it to consumers.

“This year we are leveraging the iPitch platform to seek breakthrough innovation and new products in the field of ‘wound care’ which we know is ready for disruption in the consumer health space. Research tells us that overwhelmingly consumers are seeking ‘self-care’ options for the management of their everyday health and wellbeing,” said Filomena.

“This particular iPitch challenge aims to discover innovative solutions across the wound care cycle from ‘clean and treat’ to ‘wound healing and recovery’ through to ‘scar minimisation’.”

“With our global network of innovation and distribution partners, and expertise in acquiring, building and launching trusted consumer healthcare brands, iNova is a great partner of choice for product developers, owners and licensors,” continued Filomena.

With a trusted reputation among consumers and healthcare professionals, iNova is recognised as an innovative go-to partner of choice in the consumer health industry. The company is uniquely positioned to offer access to well-established operating platforms and broad distribution networks across Asia, Middle East, Africa, Europe, Australia and New Zealand.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Latest stories

Related stories

Axtria Scales Forward Deployed Engineering Team to 1,000 Experts

Global data analytics provider Axtria Inc. announced plans on...

FDA Releases Proposed Commitment Letter for Next Generic Drug User Fee Agreement

Following months of negotiations with industry stakeholders, the US...

Buying Guide: How to Source High-Quality Selank for Research

Peptide research continues to expand across academic and independent...

CSPC Pharmaceutical and AstraZeneca form Biologics Joint Venture

CSPC Pharmaceutical and AstraZeneca have signed a joint venture...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »